Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in December

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 10,100 shares, an increase of 1,920.0% from the December 15th total of 500 shares. Based on an average daily volume of 21,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Xenetic Biosciences Trading Up 5.7 %

Shares of XBIO stock opened at $4.08 on Tuesday. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The stock has a 50 day moving average of $4.08 and a 200 day moving average of $3.99. The stock has a market cap of $6.29 million, a P/E ratio of -1.53 and a beta of 2.22.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. On average, research analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.